The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick pickshVIVO Regulatory News (HVO)

Share Price Information for hVIVO (HVO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 28.75
Bid: 28.50
Ask: 29.00
Change: 0.35 (1.24%)
Spread: 0.50 (1.754%)
Open: 28.25
High: 28.60
Low: 28.60
Prev. Close: 28.25
HVO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Hvivo plc

3 Jan 2020 14:18

RNS Number : 7365Y
IP Group PLC
03 January 2020
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

IP Group plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

hVIVO plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

13,063,883

15.72

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

13,063,883

15.72

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

None

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

None

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

None

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

None

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

None

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

None

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

23 December 2019

Contact name:

Greg Smith

Telephone number:

0207 444 0050

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETKKNBDQBKDDDK
Date   Source Headline
17th Jul 20187:00 amRNSNotification of Major Holdings
13th Jul 20183:35 pmRNSNotification of Major Holdings
10th Jul 20187:00 amRNSNotification of Major Holdings
9th Jul 20182:37 pmRNSDirectorate Change
6th Jul 20184:40 pmRNSSecond Price Monitoring Extn
6th Jul 20184:35 pmRNSPrice Monitoring Extension
6th Jul 20187:00 amRNSNotification of Major Interest in Shares
5th Jul 20183:00 pmRNSDirector's Dealings
5th Jul 201811:05 amRNSSecond Price Monitoring Extn
5th Jul 201811:00 amRNSPrice Monitoring Extension
5th Jul 20189:05 amRNSSecond Price Monitoring Extn
5th Jul 20189:00 amRNSPrice Monitoring Extension
5th Jul 20187:00 amRNSNotification of Major Interest in Shares
3rd Jul 20187:00 amRNSNotification of Major Interest in Shares
2nd Jul 20187:00 amRNSNotification of Major Interest in Shares
28th Jun 20187:00 amRNSNotification of Major Interest in Shares
27th Jun 20187:00 amRNSNotification of Major Interest in Shares
22nd Jun 20187:00 amRNSNotification of Major Interest in Shares
21st Jun 20187:00 amRNSNotification of Major Interest in Shares
20th Jun 20182:00 pmRNSNotification of Major Interest in Shares
20th Jun 201811:05 amRNSSecond Price Monitoring Extn
20th Jun 201811:00 amRNSPrice Monitoring Extension
20th Jun 20187:00 amRNSNotification of Major Interest in Shares
19th Jun 20189:05 amRNSSecond Price Monitoring Extn
19th Jun 20189:00 amRNSPrice Monitoring Extension
18th Jun 20187:00 amRNSPositive Results for Phase IIb FLU-v Field Study
23rd May 201812:30 pmRNSResult of AGM
27th Apr 20182:00 pmRNS2017 Annual Report and Financial Statements
19th Apr 20187:01 amRNSAudited 2017 Preliminary Results
19th Apr 20187:00 amRNSChief Executive Officer Steps Down
10th Apr 20187:00 amRNSStatement regarding share price
6th Apr 20187:00 amRNSNotice of Preliminary Results
5th Apr 201812:00 pmRNSDirectors' Dealings
26th Mar 20187:00 amRNSInitial results from a Phase IIb study of FLU-v
16th Jan 20187:00 amRNSAward of Share Options
9th Jan 20187:00 amRNSDirectors' Dealings
21st Dec 20177:00 amRNSAward of Share Options
14th Dec 20172:00 pmRNSDirector's Dealings
30th Oct 20177:00 amRNSDirectorate Change
5th Oct 20177:00 amRNSDirectors' Dealings
21st Sep 20177:00 amRNSHalf-year Report
10th Jul 20177:00 amRNSDirectors' Dealings
20th Jun 20177:00 amRNSBoard Change
24th May 20172:00 pmRNSResult of Annual General Meeting
18th May 20177:00 amRNSAward of Deferred Bonus Share Options
28th Apr 20172:00 pmRNS2016 Annual Report and Financial Statements
20th Apr 20177:00 amRNSAudited 2016 Preliminary Results
13th Apr 20177:00 amRNSTrading Update
5th Apr 20177:00 amRNSDirectors' Dealings
21st Feb 20174:30 pmRNSInitiation of a Phase I clinical trial with AGS-v

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.